https://go.evvnt.com/974505-0?pid=5248 Omni Parker House
60 School Street
Boston, Massachusetts 02108
Lectures & Conferences
Maximize the Clinical and Commercial Opportunity of the Adenosine-Pathway as a Second-generation Immuno-oncology Target.
Adenosine-pathway therapies have produced a plethora of promising clinical trial data that is being met with refreshed excitement, enthusiasm, and R and D investment for adenosine-pathway targets.
With reinvigorated confidence in the field, join fellow industry and academic thought leaders at the inaugural Adenosine-Pathway Targeted Cancer Immunotherapy Summit. This is the only comprehensive forum dedicated to optimizing efficacy of adenosine-pathway targeted drugs, overcoming challenges of resistance and immunosuppression and supercharging therapeutics to patients in need.
From analyzing the latest developments in understanding adenosine signaling in the TME, to rationalizing drug combinations that enhance patient responses, and exploring tools that quantify adenosine to select patients, this is the one-stop-shop event for all things adenosine-pathway.
Harness cutting-edge insights across 3 days of exclusive content from industry heavyweights including Astrazeneca, Takeda, Corvus Pharmaceuticals, iTeos Pharmaceuticals, Domain Therapeutics and more. Leave this definitive conference equipped with novel ideas, actionable lessons learned and new connections enabling you to progress your adenosine-pathway targeted cancer immunotherapies to the clinic.
Conference + Workshop Day - Drug Developer: USD 4946.0,
Conference Only - Drug Developer: USD 2999.0,
Conference + Workshop Day - Solution Provider: USD 5846.0,
Conference Only - Solution Provider: USD 3599.0,
Conference + Workshop Day - Academic: USD 4246.0,
Conference Only - Academic: USD 2599.0
Speakers: Arabella Young, Assistant Professor in the Department of Pathology; Investigator at the Huntsman Cancer Institute, The University of Utah, Bin Zhang, Professor, Northwestern University, Carine Paturel, Senior Director, Program and Portfolio Strategy, Innate Pharma, Hui Zou, Chief Scientific Officer, Phanes Therapeutics, Kavitha Yaddanapudi, Associate Professor, University of Louisville, Kris Sachsenmeier Head, Oncology Translational Strategy: Cold-to-Hot, Takeda, Maura Rosetti, Associate Director, iTeos Therapeutics, Michail Sitkovsky, Professor and Director, Northeastern University, Murali Ramachandra, Chief Executive Officer, Aurigene Discovery Technologies Limited, Musheng Bao, Senior Director, Harbour Biomed, Norihiro Nakamura, Chief Scientific Officer, BrightPath Biotherapeutics, Paul Beavis, Associate Professor, Peter MacCallum Cancer Center, Phil Darcy, Group Leader, Cancer Immunotherapy Laboratory, Peter MacCallum Cancer Centre, Rakesh Kumar, Global Project Leader, Astrazeneca, Richard Miller, Chief Executive Officer, Corvus Pharmaceuticals, Sally Ross, Project Head, iTeos Therapeutics, Simon Robson, Professor of Medicine and Anesthesiology Harvard Medical School Scientific Founder PURINOMIA and ePURINES, Stephen Hatfield, Research Scientist, Northeastern University, Xavier Leroy, Chief Scientific Officer, Domain Therapeutics, Yvonne McGrath, Vice President Research and Development, iTeos Therapeutics, Zac Cooper, Director, Translational Medicine Lead, Astrazeneca